Kura Oncology Competitors

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Insider & Institutional Ownership

94.7% of Kura Oncology shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 11.0% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and Kura Oncology's revenue, earnings per share (EPS) and valuation.

Kura Oncology has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Kura Oncology is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ultragenyx Pharmaceutical and Kura Oncology's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Ultragenyx Pharmaceutical and Kura Oncology, as provided by MarketBeat.

Ultragenyx Pharmaceutical presently has a consensus price target of $131.20, suggesting a potential upside of 20.73%. Kura Oncology has a consensus price target of $39.5455, suggesting a potential upside of 37.12%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than Ultragenyx Pharmaceutical.

Summary

Kura Oncology beats Ultragenyx Pharmaceutical on 10 of the 13 factors compared between the two stocks.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Insider & Institutional Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 94.7% of Kura Oncology shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Arrowhead Pharmaceuticals and Kura Oncology's revenue, earnings per share (EPS) and valuation.

Kura Oncology has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Arrowhead Pharmaceuticals and Kura Oncology's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Arrowhead Pharmaceuticals and Kura Oncology, as provided by MarketBeat.

Arrowhead Pharmaceuticals presently has a consensus price target of $85.3077, suggesting a potential upside of 26.27%. Kura Oncology has a consensus price target of $39.5455, suggesting a potential upside of 37.12%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than Arrowhead Pharmaceuticals.

Summary

Kura Oncology beats Arrowhead Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

GW Pharmaceuticals (NASDAQ:GWPH) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

GW Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Insider & Institutional Ownership

81.0% of GW Pharmaceuticals shares are held by institutional investors. Comparatively, 94.7% of Kura Oncology shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares GW Pharmaceuticals and Kura Oncology's revenue, earnings per share (EPS) and valuation.

GW Pharmaceuticals has higher revenue and earnings than Kura Oncology. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GW Pharmaceuticals and Kura Oncology's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for GW Pharmaceuticals and Kura Oncology, as provided by MarketBeat.

GW Pharmaceuticals presently has a consensus price target of $204.0909, suggesting a potential downside of 6.69%. Kura Oncology has a consensus price target of $39.5455, suggesting a potential upside of 37.12%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than GW Pharmaceuticals.

Summary

Kura Oncology beats GW Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Insider & Institutional Ownership

94.7% of Kura Oncology shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 11.0% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ascendis Pharma A/S and Kura Oncology's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Ascendis Pharma A/S and Kura Oncology, as provided by MarketBeat.

Ascendis Pharma A/S presently has a consensus price target of $187.6667, suggesting a potential upside of 52.69%. Kura Oncology has a consensus price target of $39.5455, suggesting a potential upside of 37.12%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Ascendis Pharma A/S is more favorable than Kura Oncology.

Risk and Volatility

Ascendis Pharma A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ascendis Pharma A/S and Kura Oncology's revenue, earnings per share (EPS) and valuation.

Kura Oncology has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Kura Oncology beats Ascendis Pharma A/S on 7 of the 13 factors compared between the two stocks.

Kura Oncology (NASDAQ:KURA) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

94.7% of Kura Oncology shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 11.0% of Kura Oncology shares are owned by company insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Kura Oncology and TG Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Kura Oncology and TG Therapeutics, as provided by MarketBeat.com.

Kura Oncology presently has a consensus target price of $39.5455, suggesting a potential upside of 37.12%. TG Therapeutics has a consensus target price of $64.00, suggesting a potential upside of 39.37%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TG Therapeutics is more favorable than Kura Oncology.

Volatility and Risk

Kura Oncology has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Valuation & Earnings

This table compares Kura Oncology and TG Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Kura Oncology has higher earnings, but lower revenue than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Kura Oncology beats TG Therapeutics on 8 of the 13 factors compared between the two stocks.

Kura Oncology (NASDAQ:KURA) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

94.7% of Kura Oncology shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 11.0% of Kura Oncology shares are owned by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Kura Oncology and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Kura Oncology and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Kura Oncology presently has a consensus target price of $39.5455, suggesting a potential upside of 37.12%. Ionis Pharmaceuticals has a consensus target price of $57.9091, suggesting a potential upside of 41.14%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Kura Oncology.

Volatility and Risk

Kura Oncology has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Valuation & Earnings

This table compares Kura Oncology and Ionis Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Ionis Pharmaceuticals beats Kura Oncology on 8 of the 13 factors compared between the two stocks.